Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced the upcoming presentation of preclinical data for its drug candidates at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19, 2023. Highlights include the IND filing for DCC-3084, a pan-RAF inhibitor, expected in the second half of 2023. The company also plans to initiate two new combination studies for DCC-3116 targeting GIST and colorectal cancer. Furthermore, DCC-3009, a pan-KIT inhibitor, shows promise with its broad mutation coverage. A virtual investor event is scheduled for April 18 at 6:30 PM ET to discuss these advancements.
- DCC-3084 expected to be filed for IND in 2H 2023, broadening pipeline.
- DCC-3116 shows promising preclinical data for GIST and colorectal cancer.
- DCC-3009 demonstrates potential as a best-in-class pan-KIT inhibitor.
- None.
– First Preclinical Data for Pan-RAF Inhibitor DCC-3084 to be Presented; IND Filing Expected in Second Half of 2023 –
– New Preclinical Data Supports ULK inhibitor DCC-3116 in Combination with QINLOCK® in GIST and in Combination with Encorafenib and Cetuximab in Colorectal Cancer; Expects to Initiate Two New Combination Escalation Studies in Second Half of 2023 –
– New Pan-KIT Development Candidate DCC-3009 for GIST Demonstrates Potential Best-in-Class Profile with Broad Coverage of KIT Mutations with High Selectivity –
– Company Discloses New Research Programs Focused on Novel Integrated Stress Response Targets GCN2 and PERK –
– Company to Host Virtual Investor Event on
“We are excited to share new preclinical data that demonstrate the breadth and depth of our research capabilities based on our proprietary switch-control kinase inhibitor platform and its ability to generate new opportunities for potential first- and best-in-class kinase inhibitors,” said
Copies of the abstracts are available on AACR’s website. Presentation details are as follows:
Poster Number: 4872
Title: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models
Presenter:
Session Date:
Session Time: 1:30 –
Poster Number: 1377
Title: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models
Presenter:
Session Date:
Session Time:
Poster Number: 4033
Title: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models
Presenter:
Session Date:
Session Time:
Poster Number: 4045
Title: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
Presenter:
Session Date:
Session Time:
Poster Number: 4938
Title: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors
Presenter:
Session Date:
Session Time: 1:30 –
Poster Number: 1639
Title: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents
Presenter:
Session Date:
Session Time:
Poster Number: 1640
Title: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents
Presenter:
Session Date:
Session Time:
Poster Number: 1613
Title: Dimerization-induced activation of the Integrated Stress Response kinase PERK by an investigational small molecule modulator, DP-9024
Presenter:
Session Date:
Session Time:
Conference Call and Webcast
Deciphera will host a virtual investor event on
About
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding the potential for our preclinical and/or clinical stage pipeline assets to be first-in-class and/or best-in-class treatments; plans to file an IND for DCC-3084 in the second half of 2023; plans to initiate two new combination escalation studies with DCC-3116 in the second half of 2023 in GIST and CRC; the potential for DCC-3009 to be a broad-spectrum KIT inhibitor in GIST. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates and in additional indications for our existing drug, the preclinical or clinical results for our drug candidates, which may not support further development of such drug candidates, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized and other risks identified in our
Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005850/en/
Investor Relations:
Deciphera@argotpartners.com
212-600-1902
Media:
david.rosen@argotpartners.com
212-600-1902
Source:
FAQ
What is the DCC-3084 IND filing timeline for Deciphera Pharmaceuticals?
What new studies is Deciphera Pharmaceuticals initiating?
When will Deciphera Pharmaceuticals present at the AACR Annual Meeting 2023?
What is the focus of Deciphera Pharmaceuticals' DCC-3009?
